Human Mobilized Peripheral Blood Leukopak, Fresh

Primary human cells, fresh

Human Mobilized Peripheral Blood Leukopak, Fresh

Primary human cells, fresh

Catalog #
(Select a product)
Primary human cells, fresh
Request Pricing
Add to Wish List

Product Advantages


  • Obtain enriched CD34+ hematopoietic stem cells from a single donor

  • Ensure consistency across your experiments by minimizing donor-to-donor variability

  • Enable scale up of your hematopoietic and progenitor stem cell studies


Overview

Obtain large numbers of single-donor CD34+ hematopoietic stem and progenitor cells (HSPCs) from peripheral blood leukopaks mobilized with granulocyte colony-stimulating factor (G-CSF), plerixafor, or G-CSF and plerixafor (Combo). Using fresh mobilized leukopaks as a rich source of circulating CD34+ cells from a single donor minimizes donor-to-donor single-cell variability, ensuring consistency across your experiments and allowing scalability of your stem cell studies.

Donors are mobilized with one of the following:
• G-CSF (NEUPOGEN®) or filgrastim: a maximum of 10 µg/kg/day of G-CSF for 5 days prior to collection
• Plerixafor (Mozobil®): a maximum of 0.24 mg/kg plerixafor for 1 day prior to collection
• G-CSF and plerixafor: a maximum of 10 µg/kg/day of G-CSF for 5 days prior to collection and a maximum of 0.24 mg/kg of plerixafor for 1 - 2 days prior to collection

Each leukopak is a highly concentrated, low-volume apheresis collection from a single, normal donor, using Institutional Review Board (IRB)-approved consent forms and protocols. A full-sized leukopak is produced from ~2 - 3x blood volumes using the Spectra Optia® Apheresis System, with acid-citrate-dextrose solution A (ACDA) as the anticoagulant. Donors are screened for HIV-1, HIV-2, hepatitis B, hepatitis C, human T-lymphotropic virus types I and II (HTLV-I/-II), syphilis, and West Nile Virus (WNV). The product will be shipped with a Certificate of Analysis (CoA) containing the reported total nucleated cells, viability, CD34+ cell frequency, standard donor information, HLA results, and full flow cytometry panel showing viable cells, CD34+ cells, monocytes, B cells, NK cells, and CD4+ and CD8+ T cell populations.

Certain products are only available in select territories. Please contact your sales representative or Product & Scientific Support at techsupport@stemcell.com for further information.

Browse our Frequently Asked Questions (FAQs) on Primary Cells.

NEUPOGEN® and Mozobil® are registered trademarks of Amgen Inc. and Genzyme Corporation respectively.
Subtype
Fresh
Cell Type
Hematopoietic Stem and Progenitor Cells, Leukopaks, T Cells
Species
Human
Cell and Tissue Source
Peripheral Blood
Application
Cell Culture, Cell Isolation, Characterization, Expansion, Flow Cytometry
Area of Interest
Angiogenic Cell Research, Cancer, Disease Modeling, Drug Discovery and Toxicity Testing, HLA, Immunology, Infectious Diseases, Stem Cell Biology, Transplantation Research, Cell Therapy Development
Donor Status
Normal

Data Figures

Human Mobilized Peripheral Blood Leukopak, Fresh

Figure 1. Mobilization Regimens of Leukopaks Mobilized with G-CSF, Plerixafor, or a Combination of G-CSF and Plerixafor (Combo)

Normal donors are mobilized with specified doses of granulocyte colony-stimulating factor (G-CSF), plerixafor, or a combination of both mobilizing agents prior to collection. The dosage for each mobilizing agent can be found on the Product Information Sheets (PISs). For each regimen, first collection only, second collection only, and both collections (first and second) are available as product options.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
200-0602, 200-0603, 100-1101
Lot #
All
Language
English
Catalog #
200-0608, 200-0607, 100-1103
Lot #
All
Language
English
Catalog #
200-0604
Lot #
All
Language
English